`
`OQHOJN
`
`9 MERCK
`
`Merck & Co.,lnc.
`
`
`
`LABORATORY NOTEBOOK
`
`8/21
`
`Merck Exhibit 2143, Page 1
`Mylan v. Merck, IPR2020-00040
`
`

`

`
`
`
`
`kfluxm.46"
`
`
`
`
`MERCK & CO., INC.
`
`NOTEBOOK PROCEDURE*
`
`
`
`Inc. and will contain confidential, proprietary, and trade secret
`This notebook is the property of Merck and Co.,
`
`information. The notebook records are important legal documents essential for obtaining patent protection on inventions
`
`
`and federal approval for our product applications.
`It
`is assigned to you. remains your responsibility while in your
`
`
`possession, and should be retained on Merck premises except when required for conducting buSiness or experiments on
`non-Merck premises or when transporting it between Merck buildings. Should you transfer to another Department or
`
`
`Division. this notebook and all ancillary data related to the experiments in it must be returned to the closest Research
`
`
`Information-MRL (RI) Site for disaster protection; if required again, it can be charged out to anyone with legitimate need.
`
`
`All incomplete notebooks will periodically be protected by microfilming or optical scanning, according to a schedule
`maintained by RI. This notebook Will serve as a primary source of experimental results. However, the use of a notebook
`
`
`is not restricted to experimental work, but includes all matters for which a readily identifiable, properly wnnessed, and
`dated record may be useful (government regulations, litigation, patent purposes, etc). To assure that this notebook is a
`
`
`useful document, follow these procedures.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`I)
`
`Enter directly in this notebook all your objectives,
`ideas. experimental plans, experimental data, obser-
`vations, calculations, clc. Do not put data on loose
`sheets and then transcribe them to this book.
`
`indelible ink, preferably
`2) Make all entries in dark,
`black, using a pen which creates an impression (e g..
`ballpoint).
`
`9)
`
`3) All entries should be from a single author; entries by
`others should be clearly identified.
`
`4)
`
`taping over, or
`Erasures, whiting out, writing over,
`pasting over are not permitted. Make corrections by
`lining out with a single line (do not obliterate entry),
`initialing. dating, and explaining.
`
`5) All entries must be made in the notebook at the time of
`the experiment. The date of each recorded experiment
`must be entered in the notebook using a non-
`ambiguous Merck Standard format
`(e.g.,
`l5 Dec.
`1997). Each day‘s entries must be signed and dated by
`the user
`immediately below the last entry.
`The
`signature
`should
`include
`first name,
`initial,
`and
`surname
`(or what
`is
`commonly
`used
`by
`the
`investigator on
`legal documents); when multiple
`entries are made on different dates, each entry should
`be dated and signed.
`
`6) Write on both left- and right-handed pages of the
`book.
`Include all observations, notes,
`references,
`quotations, discussions, calculations, sketches, clc.
`
`7)
`
`by
`identify
`clearly
`experiments,
`recording
`ln
`appropriate reference: starting materials, end products,
`protocols,
`controls,
`results,
`conclusion,
`cross-
`references, etc.
`
`8) The record must be continuous so that no suspicion of
`interpolation,
`falsification, or amendment
`can be
`aroused.
`Accordingly, all entries must be made
`consecutively with no blank pages. Vacant spaces on
`
`as
`such
`records
`ancillary
`essential
`l0) Any
`photographs, computer printouts, spectra, graphs,
`memos.
`technical
`reports,
`etc. which may
`substantiate or validate your notebook should be
`referenced to the notebook number and page and
`be kept together as a reference to that notebook.
`A reference to the ancillary data should also be
`entered on the notebook page.
`
`ll) Complete a Table of Contents or index to enable
`ready access in the future by yourself or others.
`Pages are provided for this purpose in the front of
`the book.
`Index pages for unbound notebooks
`may be obtained from Rl.
`
`l2) The records must be maintained in compliance
`with your written departmental procedure on
`keeping laboratory notebooks.
`
`
`
`
`
`
`
`a page should be marked out With a diagonal line
`or an X dated, and initialed. All entries related
`to
`previously
`numbered
`and
`paginated
`experiments must be designated by a reference in
`the margin.
`
`Each page must be countersigncd by someone not
`likely to be a co-inventor but who understands the
`significance of the recorded experiments. Counter-
`signing should be done within a reasonable time
`after the experiment. NOTE:
`If the Standard
`Operating Procedure (SOP)
`for the experiment
`specifies
`the
`frequency of
`countersignature,
`countersignature
`should
`follow that
`SOP
`conSistently (e.g., if the SOP states that counter-
`Signature WI“ occur at
`the completion of each
`experiment. then it should occur one time at the
`end of each experiment; if the SOP states weekly
`countersignature will occur, then countersignature
`should be accomplished weekly).
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`*Complele instructions are in MRL Policies, Procedures and Charters Manual, Policy 23,
`“Writing and Maintaining Preclinical Laboratory Records”, available from Research Information, MRL.
`
`
`May, 1998
`
` Merck Exhibit 2143, Page 2
`
`8/21
`
`Merck Exhibit 2143, Page 2
`Mylan v. Merck, IPR2020-00040
`
`

`

`
`:'
`hi
`‘
`NOTEBOOK NUMBER: Q6 ’80
`
`
`
`f
`
`’
`"
`
`.
`
`.
`
`,
`
`‘
`
`-
`
`.
`ASSIGNED TO:
`Print
`'Eebecm ‘
`
`Ska/Hz,
`
`Signature
`DATE—4%
`
`L8
`
`MERCK
`
`Merck & Co.,lnc.
`
`PAGES
`
`1
`
`TO [53
`
`.
`
`IMAGED BY
`
`RESEARCH INFORMATION
`ON :1 Santa 3023.
`
`RETURN TO RI iF CHANGES
`OR ADDITiONS WERE MADE
`
`LABORATORY NOTEBOOK
`
`Merck Exhibit 2143, Page 3
`
`8/21
`
`Merck Exhibit 2143, Page 3
`Mylan v. Merck, IPR2020-00040
`
`

`

`
`
`g i 1
`
`..
`
`- i E I
`
`I?
`
`s
`-'
`
`:
`
`z I l l I | I i|
`
`TABLE OF CONTENTS
`
`(Please list keywords or subject information for each page or series of pages)
`
`P 1’
`15
`egsmemL ormu/(IMS
`,v‘
`:2247l5 8&Pe
`4 .
`., 471; L/221./ solwili
`iVLDMSO
`5
`u 14A 3_
`. ”22: W /
`I
`m Ii
`.'22 7(3’
`I‘m/Illa, I ’
`IS
`.~ 2
`I
`-211!“ I" .,
`lug“;
`i'A‘A‘AJiQAI‘" ‘1'
`Jig-quzouui 1’. NW IL L-2247csmdafi 8 IO
`I 1'
`s L’zzmz «Lapin
`H
`TWZS’hm'm/lo "'6 eeci or
`4’
`~ mu: ‘,(ayd—
`3m L/ 2 ’16 rmwQLUh‘m/LS
`W L—224 ) W104! are,
`m1“ .5 -
`I...”
`
`Iz’lco
`J7
`17:2
`
`_
`_
`_
`_
`_
`_
`_
`_
`_
`
`v
`I'il
`L
`( wQDF‘. l
`W 2 1.224713Doe oi,
`VLCMSW
`Is u, .o,
`’27,
`Jun " AM I ““4144“
`Mir/“L ’93.. aiming I 1:22 ”(I
`WM 1.2' 4 u. on,
`9412164111; gin l
`:44
`I’
`'4
`
`I. 23
`I 22
`
`z 2152
`t “sum;
`' ,
`,
`9
`i -
`'. 40
`
`7
`
`
`
`lllllllllllllljllljlllllll||||
`
`Merck Exhibit 2143, Page 4 '\
`Mylan v. Merck, |PR2020-00040
`
`8/21
`
`Merck Exhibit 2143, Page 4
`Mylan v. Merck, IPR2020-00040
`
`

`

`8/21
`
`
`
`TABLE OF CONTENTS
`(Please list keywords or subject information for each page or series of pages)
`
`1
`
`5‘
`
`é
`
`3
`I
`4'
`
`‘
`l
`
`'
`
`I.
`1
`
`.
`‘1‘
`g
`I
`{
`J
`‘
`T
`,l
`
`.
`
`E“
`|
`
`.
`
`
`,
`,
`1’
`‘I
`-.
`.3!
`
`.5.
`
`i
`°
`~000§84884
`_
`a”
`am 4‘00 - Z V 4 “Jam
`“4.44' L000 ‘ Z
`
`Mal-4.}-
`'u 4.; 4:4.
`
`
`4“ 44,44 '
`- ~0005848
`4
`4' ‘
`' U
`,
`flw'm‘h .ru‘u‘A; -.
`'
`
`.
`L}
`'—54
`65’
`57-452 laws 2%
`6%
`
`’
`
`,
`
`I
`
`.
`
`‘
`.
`'
`(‘34 4!» M70 2.7
`~44 97
`4,930
`
`
`
`I
`
`I
`
`um
`.
`'7
`‘
`I
`.0
`’78 84
`"22 7154305 0e
`.4." mm 1'2
`
`.m .. MOW 858495
`444; Inc! 44419444
`= 1:?385543
`gg’
`rug-Mur‘wum . L58' - .
`8 4:4 633—6? .
`Jh‘ljn m.
`L"2 | 60 AS”.
`CW’Q'
`IO} IDS—IO
`9mm»ob;
`— 2 {405? [um
`60
`£44.42argyle“ 'Lr22 m+wtm .
`4 w 0 Hz
`[0|
`‘1be ‘.L,, 5.1.5144
`oz 10‘? Ho
`L'OZZLWIS9474; Li a u
`ID ’I)? 12
`ILJL'IIOMIIsu'ITSo “:44
`HI
`-
`a! 414 AAAM'ulr a. L 221%?005501?) I3.
`“WV tr
`'a
`'5'. 2 (am/€00
`[ES-ell H9 E7
`1
`SNJQJD .5 L~e>qozso 3002mm
`H? I20 IZZAZ’Q
`|
`: Mb; I: 4'. LHZRM‘
`ZS"! ’
`|_Hrm I'JI‘di‘L A ‘
`'L'ZQ
`'2 "2'2— IQS '8’5
`L 4» Ln _ L— oaoq—oo 00¢
`@043
`Mr3 l~4M._ , «6144,4Lr4t132 3g
`
`.
`I
`
`'
`’
`‘
`1
`1
`'
`
`: i1
`
`.3;
`lllllllllllllljllflllllllillll
`
`
`8/21
`
`Merck Exhibit 2143, Page 5
`Mylan v. Merck, IPR2020-00040
`
`

`

`
`
`
`
`TABLE OF CONTENTS
`(Please list keywords or subject informatiOn for each page or series of pages)
`
`, ,»,
`
`I
`
`I 4
`’0 0—2‘.4:A“
`\,i’ ‘ ‘4 ’uh ’5 L‘
`35 I3
`'VJ’AlA‘L JD" M ' i L722 of! I “'4'14;fl‘v..4L"4 A
`I.
`, 33
`(“34.55. --
`- gnaw o
`i5~
`m. o. L—zzs...67 Lame
`4.- 42
`I
`M' . v —22
`43- ‘
`W1.” 1 W44!’
`I 5- L/,
`W11.” v‘. 1‘22 1
`'MO.
`I
`A
`‘
`/
`‘
`‘ u u (Qua/L 1'! I .I
`|
`N. L-zz 715-0042901117
`.,
`a. 4247!
`’
`'
`1485/46?
`M? {H XRPDIW « 4 1:22
`I‘Ov/SZ
`
`n
`
`I 144
`
`a-,_..____
`
`— ‘
`
`Jllllllllllllljflfllll“Will
`
`'
`
`*
`..
`
`ii":
`
`8/21
`
`Merck Exhibit 2143, Page 6
`Mylan v. Merck, IPR2020-00040
`
`

`

`
`
`132
`
`
`
`8/21
`
`Merck Exhibit 2143, Page 7
`Mylan v. Merck, IPR2020-00040
`
`

`

`—8/21
`
`l7 44p
`.4 ’
`
`.02
`'
`1
`
`.
`‘émAmiz46.114 ga—me—W
`
`135
`
`s , k/Tlmwm LZZIS‘éflpMflMQ
`MafiLt/«Wmoow. m
`“A“
`'Qfflm_ WW70
`ma, IA
`.’__i4.~ Cg
`"
`r
`(LL
`;
`I‘}
`,
`—__‘ ,1,» d,“ ‘
`
`,
`
`A
`
`‘
`
`$-49 av
`\,
`‘cc/T:\%Mmaggm‘ hag a; Lama—0095001
`
`:
`
`w . , , moiogfimmMLme
`Mg3.7L?
`_E_C’_,fi_§
`
`II’W
`
`
`
`
`
`, am...— lllllllllllllllloljlljlllllllllltlll
`
`\ae BeLW
`
`[Mu
`
`
`
`Me'rck Exhibit 2143, Page 8
`Mylan v. Merck, |PR2020-00040
`
`8/21
`
`Merck Exhibit 2143, Page 8
`Mylan v. Merck, IPR2020-00040
`
`

`

`Supp Mn: Tabb @‘Fdaja.’ 2680457“!
`léaJrMerMflmph: 2(9186 4372 137
`
`
`
`I-
`
`M:Wa
`
`I
`I
`Adsorption/Desorption lsotherm
`L-221869 phoszphorlc aCId salt (25 C)
`.
`‘
`
`gu may:
`
`I
`7' r '
`'
`
`——~————+§— a:
`200
`
`'
`
`'
`
`/
`
`so. :00
`‘
`’6 25 000
`U)
`E
`(V 20 000
`g
`°\° 15.000
`w
`.5
`4:
`0" 10000
`._
`6
`g
`
`
`
`
`0
`
`20
`
`40
`
`-
`60
`
`o
`AR”
`
`80
`
`100
`
`5'000
`0 000
`~
`
`5—o—Adso uon'
`'
`'9
`” “’ DESU’E“°"I_
`
`_‘
`
`k
`‘
`'
`
`V
`
`3
`
`0
`
`g g p
`
`no Ini-
`5 no nun
`a mo vn at
`
`mama: Ish
`ls
`0W
`W Sn» mu
`23mm
`Ewan-x19
`mm.
`mm
`—— sum. mu m u: u mums:
`«mama-:2
`was
`094v
`—-——-— Mu an
`5 ma
`mm
`«m
`Mn am; I'm
`an nun
`Ewlrm
`as 'c
`was
`com an 15 n
`_.___ unearn-
`mo nun
`Em-I ca
`nmno v: s m
`unsup-
`unsustanmu
`onm Inavl
`Loo min or
`Exam
`mama:
`m sum
`154910
`nan:- Wm
`w-gm 5-!va sum
`mm
`5 am
`mg
`deg C
`‘s
`In
`an:
`own
`2549
`”a
`u 7
`am
`can
`an
`s In
`am
`a 054
`2: an
`no 3
`m as
`was
`:21:
`can
`law
`1500
`— nu
`a 271
`0 I07
`2529
`mu
`121‘
`a an
`0 Ma
`25 n
`24 81
`nu
`a no
`a n:
`um
`34 an
`m 1
`a an
`o m
`25 21
`N n
`no I
`a m
`a 2m
`25 as
`u n
`__ um
`um
`02:5
`2320
`and
`um
`am
`am
`nae
`a a1
`my
`um
`am
`252:
`an
`mm
`was
`mu
`2129
`59.91
`m 5
`a m
`oou
`an
`a n
`:2? 1
`am
`4999
`an
`1417
`we
`am
`us:
`25:5
`ans
`:14 1
`am
`am
`a 25
`n n
`5a: a
`can
`11:51
`as z-
`u m
`la 5
`us:
`5131
`2525
`3502
`m ‘
`w an
`2‘ m
`u u
`m m
`951 I
`um
`um
`52.
`com
`um:
`am
`3542
`at:
`55.32
`um
`um
`um
`:52:
`50.27
`":1 u
`a use
`no:
`2525
`75 u
`"on
`an
`4 :22
`an
`m»
`"an
`un
`am
`2-2:
`um
`um
`um
`us:
`a as
`com
`moo
`use
`zns
`2525
`55m
`I137!
`was
`1:15
`25::
`so 1!
`my
`a a
`ma
`an
`um
`um:
`um
`ms
`:52:
`«no
`12325
`a no
`I 422
`2.52s
`as as
`non
`use
`I no
`2525
`man
`man
`a so
`0 m
`as u
`u 71
`was
`on
`am
`an
`an 17
`[34,1
`um
`am
`an:
`1522
`an:
`um
`am
`nu
`ma
`1:94 a
`an
`(nu
`an
`A n
`
`
`
`
`
`Countersiu
`
`1'8 Swim—
`szlc
`
`
`
`Mylan v. Merck, |PR2020-00040
`
`8/21
`
`Merck Exhibit 2143, Page 9
`Mylan v. Merck, IPR2020-00040
`
`